Cambridge Healthtech Institute’s 10th Annual
Engineering Antibody-Drug Conjugates
Innovations in Next-Generation ADC Design
May 6-7, 2020
A successful ADC requires the combination of the right target, right antibody, right linker and the right payload. Getting it right can create ADCs that have the potential to become a life-saving medicine for many diseases, especially cancer. At CHI's Engineering Antibody-Drug Conjugates, speakers will share their creative strategies, whether in altering the antibody effector moiety, testing new payloads, selecting novel targets, or reinventing conjugation technologies, and discuss their progress to-date.
Ugly Ducklings: Why Clinical Effective Antibody-Drug Conjugates May Not Look That Pretty (at First)… and How to Spot Them
Greg M. Thurber, PhD, Associate Professor, Chemical Engineering and Biochemical Engineering, University of Michigan
ENGINEERING THE ANTIBODY EFFECTOR MOIETY
Targeted C'Dot-Drug Conjugates for the Treatment of Cancer
Greg Adams, PhD, CSO, Elucida Oncology, Inc.
Engineered Avibodies (Enhanced Diabodies) Precisely Loaded with Novel ADC Payloads that Surpass IgG-ADCs in Cancer Therapy
Peter Hudson, FTSE, PhD, Chief Scientist and CSO, Avipep Pty Ltd.
Probody™ Therapeutics in the Treatment of Cancer
Siew Schleyer, PhD, Director, Oncology Research, CytomX Therapeutics
NBE-002, An Anthracycline-Based Immune Stimulatory Antibody-Drug Conjugate (iADC) Targeting ROR1 for the Treatment of Triple Negative Breast Cancer
Roger R. Beerli, PhD, CSO, NBE-Therapeutics AG
Development of Novel Payloads for Next-Generation ADCs
Robert Lutz, PhD, CSO, Iksuda
Controlled Masking of Redox Cyclers for Intracellular Activation
Goncalo Bernardes, DPhil, Reader (Associate Professor), Chemical Bioogy, University of Cambridge
ADCs TARGETING THE TUMOR MICROENVIRONMENT
Antibody-Drug Conjugates (ADCs) and Small Molecule Drug Conjugates (SMDCs): A Comparative Analysis
Dario Neri, PhD, Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich)
TM4SF1: An Attractive Vascular and Tumor Cell Target for Antibody-Drug Conjugate Therapy
Shou-Ching Jaminet, PhD, Founder & Head of Research, Angiex, Inc.
IMB-213: A Novel Secretome-Targeted Biologic for the Selective Delivery of Immunomodulatory Payloads to Solid Tumors
Anton Neschadim, PhD, MBA, CEO, ImmunoBiochem Corporation
SITE-SPECIFIC CONJUGATION AND LINKER TECHNOLOGIES
Conjugating Payloads to Native Antibodies without the Need for Any Prior Antibody Engineering in a Single or Two Steps
Philipp Spycher, PhD, CEO, Araris Biotech AG
Achieving High DAR ADCs Using Site Specific Cysteine-Based Conjugation
Amit Kumar, PhD, Scientist, AstraZeneca
* The program is subject to change without notice, due to unforeseen reason.